Precision Treatment Becomes a New Trend Mr. Jiang’s case is a microcosm of the Department of Cardiology at Shulan Hospital exploring precision treatment for cardiovascular diseases. In recent years, with the development of medical technology, the treatment of cardiovascular diseases has evolved from traditional "symptomatic treatment" to the "targeted treatment era," bringing new hope to more patients.

Minimally invasive surgery For Lung Cancer has achieved major breakthroughs. Assisted by thoracoscopy, it only requires a small incision of 3 cm. It reduces the need for blood transfusion—95% of patients do not require transfusion. The operation time is shortened to within 2 hours, and the hospital stay is reduced from two weeks to one week. It improves the radicality of the surgery, increasing the 5-year survival rate by 6% and significantly enhancing the quality of life.

After Varian launched HyperSight and it was implemented clinically, how did opinions from the frontlines change? If you ask a radiologist: "Can I use HyperSight to replace the department’s 256-slice CT for hospital-wide cardiac coronary angiography screening?" Answer: No need. Physical structure dictates high-end spiral CT’s dominance in ultimate SNR. However, in the context of tumor diagnosis, this gap is clinically imperceptible.

On September 25, the research team led by Shen Zhongyang and Wang Shusen from Tianjin First Central Hospital, together with Deng Hongkui's team from Peking University/Changping Laboratory, published a landmark paper in the top journal Cell. For the first time globally, they achieved clinical functional cure of type 1 diabetes through innovative stem cell-derived islet transplantation. The patient no longer required exogenous insulin therapy during the 1-year follow-up period.

Driven by continued Chinese innovation, robust market demand, and industrial upgrades, the DBS industry is poised for a significant development period. It is expected that China will play an increasingly pivotal role in the field of neuro-modulation, offering more "Chinese Solutions" to global neurological disorder patients in the years to come.

Early-stage, radiation-sensitive tumors: Curative radiation (goal: cure). · Need to shrink tumors preoperatively or eliminate residuals postoperatively: Adjuvant radiation (goal: prevent recurrence). · Advanced cancer with severe pain, bleeding, or compression: Palliative radiation (goal: reduce suffering). Radiation therapy is personalized. Consult doctors/medical physicists for tailored plans to avoid detours.

The procedure was performed percutaneously under DSA and ICE guidance. Post-procedure ultrasound confirmed the bioabsorbable PFO occluder had good morphology and position, complete closure with no residual shunt, no pericardial effusion, and no adverse reactions before or after closure, indicating successful closure.

We are honored to announce that HANGZHOU MEDTOURCHINA TECHNOLOGY CO., LTD has been officially admitted as a BLUE Member of the Health Tourism Development Center of Islamic Countries (HTDC)! 🌍

We’re delighted to announce that MedTourChina has officially signed a Framework Strategic Cooperation Agreement with Healtra, a doctor-led healthcare cooperation. This partnership marks the beginning of a new phase of collaboration between China and the GCC region, focusing on knowledge exchange, medical coordination, and healthcare innovation.